• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer
【2h】

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer

机译：在局部晚期直肠癌中将奥沙利铂加入标准新辅助放化疗中的临床获益：一项荟萃分析：奥沙利铂在直肠癌新辅助治疗中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract. Background: To evaluate the treatment tolerance\udand clinical outcomes in patients aged 70 years and older with\udlocally advanced oropharyngeal cancer treated by definitive\udintensity-modulated radiation therapy (IMRT). Patients and\udMethods: We retrospectively analyzed 15 consecutive elderly\udpatients, with histologically-proven squamous cell carcinoma\udof the oropharynx, staged T3-4 with or without involved lymph\udnodes at diagnosis, who received definitive sequential IMRT\ud(70 Gy; 2 Gy/fraction). Adult Comorbidity Evaluation-27\ud(ACE-27) score was calculated and its influence on treatment\udtolerance and clinical outcomes was analyzed. Results: A total\udof 15 patients were included with a median age of 77 years\ud(range=70-88 years). At baseline, 8 patients (53.3%) had an\udACE-27 score of 1, and the remainder (n=7, 46.7%) had a\udcomorbidity index of 0. All patients completed programmed\udIMRT treatment, without any reduction of total dose. Oral\udpain and mucositis were the most common acute side-effects,\udclassified as grade 3 in 6 patients (40%) only. Xerostomia was\udreported in 13 patients (86.7%), without severe manifestation.\udThere was no hematological toxicity. ACE-27 score was not\udrelated to higher severe acute toxicity. No patients experienced\udgrade 3 or more late toxicity. Five-year overall survival and\uddisease-free survival rates were 63.6% (95% confidence\udinterval=32.7-83.3%) and 55% (95% confidence\udinterval=24.4-77.6%), respectively. Comorbidity score did not\udinfluence survival outcomes, both overall survival (p=0.46)\udand disease-free survival (p=0.55). Conclusion: Treatment\udtolerance, as well as survival outcomes were good in elderly\udoropharyngeal cancer patients treated with definitive\udsequential IMRT. Due to age and comorbidity, no dose or\udvolume reduction for IMRT should be considered in this\udsetting of patients. A prospective randomized trial with a large\udsample size should be conducted to confirm our results
机译：抽象。背景：为了评估70岁及以上接受定性/强度调制放射治疗（IMRT）治疗的\局部局部晚期口咽癌患者的治疗耐受性和临床疗效。患者和方法：我们回顾性分析了15例经组织学证实为口咽鳞状细胞癌/口咽的连续性老年/患者，在诊断时分阶段T3-4伴或不伴淋巴结/淋巴结转移，他们接受了确定的连续IMRT \ ud（70 Gy ; 2 Gy / fraction）。计算成人合并症评估-27 \ ud（ACE-27）得分，并分析其对治疗/耐受性和临床结局的影响。结果：共纳入\ udof 15位患者，中位年龄为77岁\ ud（范围= 70-88岁）。基线时，有8例患者（53.3％）的\ udACE-27得分为1，其余（n = 7，46.7％）的\ udcomorbidity指数为0。所有患者均完成了程序性\ udIMRT治疗，且未降低总剂量。口腔\尿痛和粘膜炎是最常见的急性副作用，仅在6例患者（40％）中被分类为3级。口干症13例，占86.7％，无严重表现。无血液学毒性。 ACE-27评分与较高的严重急性毒性无关。没有患者经历\ udgrade 3或更高的晚期毒性。五年总体生存率和无无疾病存活率分别为63.6％（95％置信度/udinterval=32.7-83.3%）和55％（95％置信度/udinterval=24.4-77.6%）。合并症评分未影响所有患者的生存结局，总体生存率（p = 0.46）\无疾病生存率（p = 0.55）。结论：经定性/后继IMRT治疗的老年/咽喉癌患者的治疗/耐受性和生存期均良好。由于年龄和合并症，在此患者中不考虑IMRT的剂量或剂量减少。应进行前瞻性随机\大样本随机试验以确认我们的结果

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号